(NASDAQ: APRE) Aprea Therapeutics's forecast annual revenue growth rate of 238.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Aprea Therapeutics's revenue in 2025 is $1,284,475.On average, 1 Wall Street analysts forecast APRE's revenue for 2025 to be $885,020, with the lowest APRE revenue forecast at $885,020, and the highest APRE revenue forecast at $885,020. On average, 1 Wall Street analysts forecast APRE's revenue for 2027 to be $327,512,595, with the lowest APRE revenue forecast at $327,512,595, and the highest APRE revenue forecast at $327,512,595.
In 2028, APRE is forecast to generate $671,287,427 in revenue, with the lowest revenue forecast at $671,287,427 and the highest revenue forecast at $671,287,427.